Following antibody treatments, average Wnt1 tumor size in the anti-Gr1 group was inhibited by 53% relative to control anti-GD treated group (Fig. 6B; p = 0.034), which was similar to the levels of inhibition by anti-SDF1. This evidence concerns the gene CXCL12 and neoplasm.